• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Cayston (aztreonam for inhalation solution)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012

 

Summary View

6 ADVERSE REACTIONS

6.2 Postmarketing Experience

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS:  

  • Dyspnea

MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS:

  • Arthralgia, Joint swelling